Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $301.90, but opened at $290.50. Bio-Rad Laboratories shares last traded at $298.3270, with a volume of 57,330 shares.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the company. Wells Fargo & Company reduced their target price on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a report on Friday, May 1st. Weiss Ratings downgraded Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 6th. Royal Bank Of Canada began coverage on Bio-Rad Laboratories in a research report on Friday, May 15th. They set an “outperform” rating and a $320.00 price target on the stock. Zacks Research downgraded Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Finally, Citigroup lowered shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $375.00 to $300.00 in a research report on Tuesday, April 7th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Bio-Rad Laboratories currently has an average rating of “Reduce” and an average target price of $303.33.
Check Out Our Latest Stock Analysis on BIO
Bio-Rad Laboratories Price Performance
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.97 by ($0.08). Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The firm had revenue of $592.10 million for the quarter, compared to analysts’ expectations of $589.91 million. During the same quarter in the prior year, the business posted $2.54 earnings per share. Bio-Rad Laboratories’s revenue was up 1.1% on a year-over-year basis. Analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.42 EPS for the current fiscal year.
Institutional Investors Weigh In On Bio-Rad Laboratories
Institutional investors have recently made changes to their positions in the company. Danske Bank A S bought a new position in Bio-Rad Laboratories during the fourth quarter valued at approximately $30,000. Hollencrest Capital Management acquired a new position in shares of Bio-Rad Laboratories during the 1st quarter worth $28,000. Geneos Wealth Management Inc. increased its stake in shares of Bio-Rad Laboratories by 115.2% during the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at $47,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of Bio-Rad Laboratories by 76.9% during the 4th quarter. Farther Finance Advisors LLC now owns 184 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 80 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.
Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.
Read More
- Five stocks we like better than Bio-Rad Laboratories
- Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build
- 2 ETFs to Access the World’s Best-Performing Stock Markets In 2026
- IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story
- Alphabet Is Planning a New AI Chip. Here’s Why It Matters Ahead of Earnings
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
